Premium
Tigecycline treatment of multi‐drug‐resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia
Author(s) -
Dinleyici Ener Cagri,
Yargic Zeynel Abidin,
Bor Ozcan,
Kiremitci Abdurrahman,
Durmaz Gul
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22527
Subject(s) - tigecycline , medicine , lymphoblastic leukemia , refractory (planetary science) , sepsis , central venous catheter , intensive care medicine , antibiotics , catheter , leukemia , surgery , microbiology and biotechnology , physics , astrobiology , biology
Corynebacterium jeikeium has been recognized as an important cause of infection, particularly among neutropenic patients who have central venous catheter (CVC). Routine use of tigecycline in children is not yet approved. Here in we present a child with relapsed‐refractory lymphoblastic leukemia who was successfully treated with tigecyline due to multi‐drug‐resistant C. jeikeium sepsis without removal of CVC. Our case highlights the use of tigecycline where there are no alternatives. Further studies regarding the efficacy and safety of tigecycline in pediatric patients are needed. Pediatr Blood Cancer. 2010;55:349–351. © 2010 Wiley–Liss, Inc.